87 related articles for article (PubMed ID: 23218563)
1. Attaining and sustaining remission of predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Jan; 143(1):60-4. PubMed ID: 23218563
[TBL] [Abstract][Full Text] [Related]
2. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.
Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
Schizophr Res; 2011 Dec; 133(1-3):42-6. PubMed ID: 22000938
[TBL] [Abstract][Full Text] [Related]
3. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Levine SZ; Leucht S
Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
[TBL] [Abstract][Full Text] [Related]
4. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Apr; 145(1-3):125-7. PubMed ID: 23394742
[TBL] [Abstract][Full Text] [Related]
5. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
Danion JM; Rein W; Fleurot O
Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Müller N; Krause D; Dehning S; Musil R; Schennach-Wolff R; Obermeier M; Möller HJ; Klauss V; Schwarz MJ; Riedel M
Schizophr Res; 2010 Aug; 121(1-3):118-24. PubMed ID: 20570110
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
9. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
10. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
[TBL] [Abstract][Full Text] [Related]
11. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia.
Levine SZ; Leucht S
Eur Neuropsychopharmacol; 2012 Nov; 22(11):812-7. PubMed ID: 22507686
[TBL] [Abstract][Full Text] [Related]
12. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Engel RR; Kissling W
Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
[TBL] [Abstract][Full Text] [Related]
14. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
[TBL] [Abstract][Full Text] [Related]
15. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.
Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Heuser I; Maier W; Klosterkötter J; Falkai P; Schlösser R; Schmitt A; Riedel M; Klingberg S; Köpcke W; Ohmann C; Möller HJ
Schizophr Res; 2014 Feb; 152(2-3):478-86. PubMed ID: 23643327
[TBL] [Abstract][Full Text] [Related]
16. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
17. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Sechter D; Peuskens J; Fleurot O; Rein W; Lecrubier Y;
Neuropsychopharmacology; 2002 Dec; 27(6):1071-81. PubMed ID: 12464464
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
[TBL] [Abstract][Full Text] [Related]
19. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Emsley R; Rabinowitz J; Medori R;
Schizophr Res; 2007 Jan; 89(1-3):129-39. PubMed ID: 17095194
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Lin CH; Wang FC; Lin SC; Huang YH; Chen CC; Lane HY
Int Clin Psychopharmacol; 2013 Sep; 28(5):267-74. PubMed ID: 23778382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
